New hope for bile duct cancer: targeted drug BL-M07D1 enters final testing

NCT ID NCT07606599

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This Phase 3 trial tests a new drug, BL-M07D1, against standard chemotherapy in about 400 people with a specific type of advanced bile duct cancer (HER2-positive) that has stopped responding to platinum-based chemo. The goal is to see if BL-M07D1 can help people live longer. Participants will be randomly assigned to receive either the new drug or one of several standard chemotherapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M07D1 (a targeted drug that attacks HER2-positive cancer cells)
What this could lead to: If successful, this could offer a new, more effective treatment option for people with HER2-positive biliary tract cancer that has not responded to standard chemotherapy.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may not work better than existing chemotherapies, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, China
The First Affiliated Hospital of University of Science and Technology of China
RECRUITING

Hefei, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.